Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 95Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 16Myelodysplastic Syndromes 15Leukemia 13Leukemia, Biphenotypic, Acute 10Recurrence 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Multiple Myeloma 6Lymphoma, Follicular 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, B-Cell 3Chromosome 17 deletion 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Hematologic Neoplasms 2

Interventions

fludarabine 7Tacrolimus 6Cyclophosphamide 6Whole-Body Irradiation 5Mycophenolic Acid 5Busulfan 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Imatinib Mesylate 4Cytarabine 4Sirolimus 3Melphalan 3thymoglobulin 2asciminib 2Thiotepa 2Patient Reported Outcome Measures 2Mesna 2Bone Marrow Transplantation 2Antilymphocyte Serum 2venetoclax 1ponatinib 1pegfilgrastim 1nilotinib 1nicotinamide-beta-riboside 1methanesulfonic acid 1lonafarnib 1lestaurtinib 1glasdegib 1flumatinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid × venetoclax × Clear all
NCT01994837 2018-06-06

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

AbbVie

Phase 2 Completed
32 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡